Mounjaro vs. Farxiga
See how Mounjaro and Farxiga compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Mounjaro is an injectable dual incretin agonist that also drives significant weight loss, while Farxiga is a once-daily pill focused on heart and kidney protection.
Farxiga carries FDA approvals for heart failure and chronic kidney disease that Mounjaro does not have.
Mounjaro requires a slow multi-step dose increase over several months, while Farxiga starts at a set dose with no titration needed.
Mounjaro vs. Farxiga Drug Summary
Mounjaro
Mounjaro (tirzepatide) is a GIP/GLP-1 receptor agonist injected once weekly under the skin. It is FDA-approved to improve blood sugar control in adults and children 10 and older with type 2 diabetes. It is also used off-label for weight loss in people without diabetes.
Farxiga
Farxiga (dapagliflozin) is an SGLT2 inhibitor taken as a once-daily tablet. It is FDA-approved for type 2 diabetes, heart failure, and chronic kidney disease, helping the kidneys remove excess glucose through urine. It is also approved for children 10 and older with type 2 diabetes.
Mounjaro vs. Farxiga Side Effects
Mounjaro
Farxiga
Mounjaro vs. Farxiga Dosage
Mounjaro
Farxiga
| STAGE | DOSE | WHEN |
| Starting dose | 2.5 mg once weekly | Weeks 1-4 |
| Maximum dose | 15 mg once weekly | Week 21 onward |
| Dose changes | 5 increases | Every 4 weeks |
| STAGE | DOSE | WHEN |
| Starting dose | 5 mg once daily | At the start |
| Maximum dose | 10 mg once daily | If needed |
| Dose changes | 1 increase | As tolerated |
Mounjaro
| STAGE | DOSE | WHEN |
| Starting dose | 2.5 mg once weekly | Weeks 1-4 |
| Maximum dose | 15 mg once weekly | Week 21 onward |
| Dose changes | 5 increases | Every 4 weeks |
Farxiga
| STAGE | DOSE | WHEN |
| Starting dose | 5 mg once daily | At the start |
| Maximum dose | 10 mg once daily | If needed |
| Dose changes | 1 increase | As tolerated |
Mounjaro vs. Farxiga Indications
Mounjaro
Mounjaro is approved to improve blood sugar control in adults and children 10 and older with type 2 diabetes. It is not approved for type 1 diabetes or for weight loss on its own, though many doctors prescribe it off-label for that purpose.
Type 2 diabetes glycemic control in adults
Type 2 diabetes glycemic control in children 10+
Off-label: chronic weight management
Not approved for type 1 diabetes
Farxiga
Farxiga is approved for blood sugar control in type 2 diabetes, plus three additional uses Mounjaro does not have: heart failure, chronic kidney disease, and reduced hospitalization risk from heart disease. It is not approved to treat type 1 diabetes or diabetic ketoacidosis.
Type 2 diabetes glycemic control in adults and children 10+
Heart failure to reduce cardiovascular death and hospitalization
Chronic kidney disease to slow decline and reduce death risk
Reduce heart failure hospitalization risk in type 2 diabetes with cardiovascular risk factors
Mounjaro vs. Farxiga Pros and Cons
Mounjaro
Mounjaro tends to produce larger blood sugar reductions and more weight loss than oral diabetes pills, but it requires an injection and a gradual dose increase over months. Insurance coverage often hinges on a type 2 diabetes diagnosis, since weight-loss use is off-label.
Pros
Greater average blood sugar and weight reduction in trials
Only one injection needed per week
Dual-hormone mechanism may work when other drugs plateau
Cons
Requires self-injection rather than a pill
Boxed warning for thyroid C-cell tumor risk
Slow titration schedule takes about 5 months to reach top dose
Roughly $1,000 to $1,300 per month without insurance, before savings programs
Farxiga
Farxiga is a once-daily pill with a long track record and proven heart and kidney benefits beyond blood sugar control. It causes less weight loss than Mounjaro but carries its own risks, including genital infections and rare serious infections.
Pros
Oral tablet, no injections needed
Proven to reduce heart failure hospitalization and death
Approved to slow chronic kidney disease progression
Cons
Less effective for weight loss than Mounjaro
Risk of genital yeast infections
Rare but serious risk of Fournier's gangrene
Not recommended for glycemic control in advanced kidney impairment
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.